Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830198 | 0.91 | KMT2A (0.51) | RAB9ATSHRKDM4EKMT2AMEN1 | |
| SCHEMBL2829272 | 0.84 | KMT2A (0.52) | RAB9ATSHRKDM4EKMT2AMEN1 | |
| SCHEMBL2828891 | 0.81 | FLT3 (0.49) | RAB9ATSHRKDM4EKMT2AMEN1 | |
| SCHEMBL2827781 | 0.80 | BACE1 (0.49) | RAB9ATSHRKMT2ABACE1NPC1 | |
| SCHEMBL2827017 | 0.79 | TSHR (0.56) | TSHRKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL2829649 | 0.79 | BACE1 (0.47) | RAB9ATSHRALDH1A1BACE1PTGS2 | |
| SCHEMBL2829708 | 0.76 | KMT2A (0.46) | RAB9ATSHRKDM4EKMT2AMEN1 | |
| SCHEMBL2827089 | 0.76 | LMNA (0.46) | RAB9ATSHRKDM4EKMT2AMEN1 | |
| SCHEMBL2826364 | 0.75 | FLT3 (0.51) | RAB9AKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL2832702 | 0.75 | ADORA3 (0.46) | RAB9ATSHRKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | claimed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | claimed |
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | GABRA5, GABRA4, GABRA3 | RAB9A 1937/4885TSHR 840/4885KDM4E 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.